Viral Vectors And Plasmid DNA Manufacturing Market Poised to Expand at a Robust Pace of USD 8.6 Billion Over 2028: Grand View Research Inc.

 Viral Vectors And Plasmid DNA Manufacturing Market Growth & Trends

The global viral vectors and plasmid DNA manufacturing market size is expected to reach USD 8.6 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.8% from 2021 to 2028. The robust pipeline for gene therapies and viral-vector-based vaccines has primarily driven the market.

Amidst the COVID-19 pandemic, the demand for viral vectors has rapidly increased especially in vaccinology. This led to expanding manufacturing capabilities by operating players to meet the growing demand. The application of these vectors in vaccine development has witnessed significant growth in 2020.

Also, an increase in the number of gene therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive the demand for scalable production of gene therapy vectors. Owing to this, several private and public agencies are providing funds to accelerate advancements in the manufacturing processes for viral vectors.

Besides, the implementation of single-use technology can lead to significant savings in capital, operating costs, materials, and labor. The use of this equipment will enhance efficiency and improve flexibility, leading to high yields of the final product. Thus, advancements in single-use technology directly impact revenue growth in this space.

Request a free sample copy or view report summary: Viral Vectors And Plasmid DNA Manufacturing Market Report

Viral Vectors And Plasmid DNA Manufacturing Market Report Highlights

• The Adeno Associated Virus (AAV) segment accounted for the significant revenue share in 2020. High usage and promising results in gene therapy clinical trialshave boosted its adoption
• Moreover, several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy products, thereby driving the segment
• The downstream processing segment dominated the market in terms of revenue share. This can be attributed to the availability of advanced purification products
• Owing to the rising demand for cost-effective and scalable manufacturing processes, companies are involved in the development of the upstream cell culture processes
• This is anticipated to result in the notable growth of the upstream processing segment
• The vaccinology segment dominated the market in terms of revenue share in 2020
• The SARS-COV-2 pandemic has supplemented the use of vectors in this segment
• With the active engagement of the research community in the R&D of advanced therapies, research institutes captured the maximum revenue share in the market
• The initiation of several R&D programs by pharmaceutical and biopharmaceutical companies to combat the COVID-19 crisis would further propel market growth
• A rapidly growing pipeline of advanced therapy products for various cancer types has led to lucrative revenue generation in the cancer segment
• North America maintained its dominance in 2020 owing to the high number of entities engaged in offering products and services for viral vector manufacturing in the U.S.
• Furthermore, the remarkable success of viral vector-based Kymriah, Yescarta, and ZOLGENSMA in the U.S. has also contributed to regional dominance
• In Asia Pacific, the market is projected to witness the fastest growth rate owing to industrialization and clinical transformation of gene therapyin the region
• Companies continue to make focused attempts to expand their manufacturing facilities as well as service portfolio to maintain their market presence

Access Press Release@ https://www.grandviewresearch.com/press-release/global-viral-vector-plasmid-dna-manufacturing-market

Viral Vectors And Plasmid DNA Manufacturing Market Segmentation

Grand View Research has segmented the global viral vectors and plasmid DNA manufacturing market on the basis of vector type, workflow, application, end use, disease, and region:

Viral Vectors & Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2017 - 2028)

• Adeno Associated Virus (AAV)
• Lentivirus
• Adenovirus
• Retrovirus
• Plasmid DNA
• Others

Viral Vectors & Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2017 - 2028)

• Upstream Processing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
• Downstream Processing
  • Purification
  • Fill-finish

Viral Vectors & Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2017 - 2028)

• Antisense & RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

Viral Vectors & Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2017 - 2028)

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

Viral Vectors & Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2017 - 2028)

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

Viral Vectors & Plasmid DNA Manufacturing Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK.
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • South Africa
  • Saudi Arabia

List of Key Players of Viral Vectors And Plasmid DNA Manufacturing Market

• Merck KGaA
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Cobra Biologics
• Thermo Fisher Scientific
• Waisman Biomanufacturing
• Genezen laboratories
• YPOSKESI
• Advanced BioScience Laboratories, Inc. (ABL)
• Novasep Holdings S.A.S.
• Orgenesis Biotech Israel Ltd
• Vigene Biosciences Inc.
• General electric company (GE Healthcare)
• pharmaceuticals GMBH
• Batavia Biosciences
• Biovion Oy
• Wuxi Apptec Co Ltd
• VGXI Inc.
• Catalent Inc.
• Miltenyi Biotec GmbH
• SIRION Biotech GmbH
• Virovek Incorporation
• BioNTech IMFS GmbH
• VIVEbiotech S.L.
• Creative Biogene
• Vibalogics BmbH
• Takara Bio Inc.
• Cell and Gene Therapy Catapult Bluebird Bio Inc.
• Addgene Inc.
• Aldevron LLC
• Astellas Pharma Inc.
• BioMarin Pharmaceutical
• RegenxBio, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.